What is HC Wainwright’s Forecast for LifeMD Q3 Earnings?

LifeMD, Inc. (NASDAQ:LFMD) – Stock analysts at HC Wainwright issued their Q3 2027 earnings per share estimates for shares of LifeMD in a research report issued on Tuesday, May 26th. HC Wainwright analyst Y. Chen forecasts that the company will post earnings per share of $0.06 for the quarter. HC Wainwright currently has a “Buy” rating and a $10.00 price objective on the stock. The consensus estimate for LifeMD’s current full-year earnings is $0.04 per share.

LifeMD (NASDAQ:LFMD) last issued its earnings results on Wednesday, May 6th. The company reported ($0.20) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.06). LifeMD had a negative return on equity of 150.88% and a net margin of 2.37%.The company had revenue of $50.16 million during the quarter, compared to analyst estimates of $48.84 million.

A number of other analysts also recently issued reports on the company. BTIG Research reaffirmed a “buy” rating and issued a $10.00 target price on shares of LifeMD in a research note on Monday, May 4th. Wall Street Zen downgraded LifeMD from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th. UBS Group reaffirmed a “buy” rating on shares of LifeMD in a research note on Wednesday. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of LifeMD in a research note on Tuesday, March 10th. Finally, Weiss Ratings raised LifeMD from a “sell (e+)” rating to a “sell (d)” rating in a research note on Thursday, May 7th. Eight research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $9.14.

LifeMD Stock Up 7.8%

Shares of LFMD opened at $4.57 on Thursday. LifeMD has a 52-week low of $2.56 and a 52-week high of $15.84. The company has a market capitalization of $221.01 million, a PE ratio of 91.42 and a beta of 2.03. The stock has a fifty day simple moving average of $4.16 and a two-hundred day simple moving average of $3.78.

Institutional Trading of LifeMD

Hedge funds and other institutional investors have recently modified their holdings of the business. Prescott Group Capital Management L.L.C. acquired a new stake in shares of LifeMD during the 4th quarter worth about $2,344,000. Pier 88 Investment Partners LLC increased its position in shares of LifeMD by 25.1% during the 4th quarter. Pier 88 Investment Partners LLC now owns 74,760 shares of the company’s stock worth $255,000 after purchasing an additional 15,020 shares during the last quarter. State of Alaska Department of Revenue increased its position in shares of LifeMD by 694.2% during the 4th quarter. State of Alaska Department of Revenue now owns 20,022 shares of the company’s stock worth $67,000 after purchasing an additional 17,501 shares during the last quarter. SG Americas Securities LLC increased its position in shares of LifeMD by 13.8% during the 4th quarter. SG Americas Securities LLC now owns 25,298 shares of the company’s stock worth $86,000 after purchasing an additional 3,061 shares during the last quarter. Finally, Magnus Financial Group LLC acquired a new position in LifeMD in the 4th quarter valued at about $41,000. 35.52% of the stock is owned by institutional investors and hedge funds.

LifeMD Company Profile

LifeMD (NASDAQ: LFMD) is a U.S.-based telehealth company that delivers on-demand, membership-based virtual healthcare services. Through its digital platform and mobile applications, LifeMD connects patients with board-certified healthcare providers for diagnosis, treatment and ongoing management of a range of acute and chronic conditions. The company’s core offering centers on personalized care plans supported by prescription fulfillment, lab testing and prescription delivery services.

LifeMD’s service portfolio spans several specialty areas, including men’s health, hormonal therapy, weight management and primary care.